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Abstract
BACKGROUND—Despite clear recommendations and evidence linking colorectal cancer 
screening to lower incidence and mortality, >40% of adults are not up to date with screening. 
Existing domestic and international models of organized cancer screening programs have been 
effective in increasing screening rates. Implementing an organized, evidence-based, national 
screening program may be an effective approach to increasing screening rates.
METHODS—In the current study, the authors estimated the initial investment required and the 
cost per person screened of a nationwide fecal immunochemical test (FIT)-based colorectal cancer 
screening program among adults aged 50 years to 75 years.
RESULTS—The initial additional investment required was estimated at $277.9 to $318.2 million 
annually, with an estimated 8.7 to 9.4 million individuals screened at a cost of $32 to $39 per 
person screened. The program was estimated to prevent 2900 to 3100 deaths annually.
CONCLUSIONS—The results of the current study indicate that implementing a national 
screening program would make a substantial public health impact at a moderate cost per person 
screened. Results from this analysis may provide useful information for understanding the public 
health benefit of an organized screening delivery system and the potential resources required to 
implement a nationwide colorectal cancer screening program, and help guide decisions about 
program planning, design, and implementation.
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INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer-related death and the second 
most common cancer affecting both men and women in the United States. In 2010, 131,607 
people were diagnosed with CRC, and 52,045 died of the disease.1 In addition, the economic 
burden of CRC is substantial. The national cost of CRC care was estimated to be $14.1 
billion in 2010 and was projected to increase to $17.4 billion in 2020.2 Lost productivity 
from CRC deaths is estimated to cost $15.3 billion annually.3
Screening has been shown to reduce the incidence and mortality rates of CRC through 
prevention (identifying and removing premalignant polyps) and early detection,4 and 
screening consistently has been shown to be cost-effective or even cost-saving.5 CRC 
screening is a desirable approach to reduce CRC incidence and mortality rates and treatment 
costs.6 An investment in screening pre–Medicare-eligible individuals may result in 
significant savings to Medicare.7 The US Preventive Services Task Force recommends 
screening for CRC using fecal occult blood testing (FOBT), sigmoidoscopy, or colonoscopy 
in adults aged 50 years to 75 years.4
Despite this recommendation and the clear evidence linking CRC screening to lower 
incidence and mortality rates, many adults aged 50 years to 75 years are not receiving the 
recommended screenings.8 In 2010, only 58.6% of all adults and 20.8% of uninsured adults 
aged 50 years to 75 years were up to date with CRC screening.9 Increasing the percentage of 
US adults aged 50 years to 75 years screened for CRC is a leading national health objective 
in Healthy People 2020.10
It is well established that public health efforts to increase CRC screening would reduce the 
burden of the disease. Although the medical care system is an important partner in 
promoting and providing cancer screening services, efforts to increase screening rates in 
clinical settings are limited by the opportunistic nature of the provision of clinical services 
and suboptimal access, particularly for the uninsured. The majority of patients are offered 
screening tests when they visit a medical provider for unrelated reasons. As evidenced by 
the low CRC screening rates among the uninsured, lack of health insurance is an important 
barrier to screening.9 The Patient Protection and Affordable Care Act (ACA) helps to make 
insurance coverage more available by promoting the expansion of Medicaid programs in 
states, and by establishing a Health Insurance Marketplace. Likewise, for new private health 
insurance plans and expanded Medicaid, the ACA provides for the elimination of cost-
sharing for recommended preventive services rated as “A” or “B” by the US Preventive 
Services Task Force, such as CRC screening.11 Even with adequate health insurance, 
individuals still face obstacles to obtaining cancer screening, such as lack of provider 
recommendation, transportation or geographic access, lack of awareness, and language 
barriers. Efforts to address these hurdles to CRC screening could make the increased 
insurance coverage made possible under the ACA even more effective in increasing 
Guy et al. Page 2













screening rates. There is strong evidence for the effectiveness of interventions reducing 
structural barriers to screening, such as mailing FOBT cards.12 FOBT offers the advantage 
of being noninvasive and convenient for patients and is ideally suited for organized CRC 
screening programs. The fecal immunochemical test (FIT), one type of FOBT, has been 
shown to have improved patient acceptance and improved specificity compared with other 
guaiac-based tests.13 Mailed outreach invitations with FIT have been shown to result in 
higher screening rates compared with other approaches.14 Together, these factors suggest 
that implementing an organized evidence-based screening program using the FIT may be an 
effective and affordable approach to increase CRC screening rates in the United States.
In the current study, we modeled the initial additional investment required and the cost per 
person screened of implementing a nationwide FIT-based screening program for adults aged 
50 years to 75 years. Although similar programs have been implemented internationally or 
on a smaller scale (ie, managed care system or community health center),13,15 to the best of 
our knowledge no study to date has examined the feasibility of a national program in the 
United States. Modeling offers a means of understanding the costs and potential benefits of 
such a program, and can help inform program implementation decisions.
MATERIALS AND METHODS
Study Design and Target Population
We examined a hypothetical CRC screening program under 2 different intervention designs. 
The target population included all adults aged 50 years to 75 years in the United States 
regardless of insurance status and CRC screening status. The target population consisted of 
82.1 million adults, leading to 41.1 million being offered a FIT test each year in a biennial 
screening program.17 Using estimates from the literature, we examined the total initial (first 
2 years) annual cost and the cost per person screened under each intervention design.
Under the first scenario, a FIT kit would be mailed to every adult aged 50 years to 75 years 
(Fig. 1). Participants would be asked to complete the test and return the sample in a prepaid 
envelope. Individuals with a personal history or family history of CRC (estimated at 11%),17 
would be instructed to discuss CRC screening with a health care provider rather than 
completing the test kit. A follow-up educational reminder letter would be sent to individuals 
who did not initially return the FIT test.
Under the second intervention scenario, all adults aged 50 years to 75 years would be mailed 
a postcard inviting them to participate in the screening program (Fig. 2). Individuals 
interested in participating would be instructed to return the postcard indicating their intent, 
whereas those with a personal history or family history of CRC would be instructed to 
discuss screening with a health care provider. All individuals returning a postcard would be 
sent a FIT kit and instructed to complete the test and return it in a prepaid envelope.
Participation Rates
Under the first scenario, in which the initial mailing included the FIT kit, we assumed 
participation rates based on data from 2 randomized trials.18,19 We assumed an initial FIT 
kit return rate of 18%,18 and a 33% increase with the use of educational reminder letters,19 
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resulting in a final participation rate of 24%. Under this scenario, 8.7 million individuals 
would be screened for CRC annually during the first 2 years (Table 1).16–29
Under the second scenario, in which an advanced notification postcard would be sent 
followed by a FIT kit, on the basis of data from a randomized trial, we assumed that 33% of 
the target population would express interest in participating.30 Using results from the same 
trial, we assumed a 78% return rate from the FIT kit mailing,30 resulting in a final 
participation rate of 26%. Under this scenario, 9.4 million individuals would be screened for 
CRC annually in the first 2 years (Table 2).16,20–30
Detection Rates
On the basis of data from a randomized trial, we assumed a positive FIT rate of 5.5% using a 
threshold of 100 ng/mL as a positive test.20 In addition, we assumed a 75% adherence rate to 
a follow-up colonoscopy, on the basis of findings from observational and randomized 
studies.21–23 Among those patients with a positive FIT receiving a colonoscopy, we 
assumed 9% would have cancer, 43% would have advanced adenomas, and 20% would have 
nonadvanced adenomas on the basis of results from a randomized trial.20 Screening program 
participants with adenomas or cancer would receive appropriate treatment and surveillance 
colonoscopies.31
Cost Assumptions
Costs were based on estimates from other modeling studies and from the Centers for Disease 
Control and Prevention (CDC) Colorectal Cancer Screening Demonstration Program. We 
included estimates of program administrative costs, including general program 
administrative costs, identifying eligible adults, public education and outreach, quality 
assurance, partnership development, data collection, and program evaluation. The costs 
associated with data collection would provide information regarding patient screening and 
allow for the seamless continuation of the program beyond its initial implementation. We 
assumed the costs of mailing the FIT kits were $2 each, reminder letters were $0.50 each, 
FIT kit return fees were $2 each, and test processing fees were $7 each. We assumed the 
costs associated with improving participation and adherence among individuals with a 
positive FIT to be $153 per positive FIT on the basis of data from the demonstration 
program.29 The cost of diagnostic colonoscopies and primary care visits were included for 
the uninsured population aged 50 years to 64 years; individuals aged ≥65 years were 
assumed to be insured through Medicare. Each colonoscopy without a polypectomy was 
estimated to cost $587, whereas each colonoscopy with a polypectomy was estimated to cost 
$76525 for the 78% of cases in which polyps are detected.20 We assumed that 80% of 
individuals with a positive FIT would visit a primary care provider.32 The cost of primary 
care visits was based on Medicare reimbursements.24 On the basis of data from an integrated 
health care delivery system and observational studies, colonoscopy complications were 
assumed to occur in 2.4 per 1000 colonoscopies, with an average cost of $6233 per 
complication.17,26–28,33 Among the insured patients, service delivery costs would be 
accounted for through the usual care system, as is currently the case. The amount spent on 
the CDC Colorectal Cancer Screening Demonstration Program annually was subtracted 
from the total gross annual cost to determine the initial additional investment required each 
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year. The cost per person screened was determined by dividing the total gross annual cost by 
the number of individuals screened annually.
Mortality Reduction
We estimated the effect of the screening program on CRC mortality using estimates from 
the literature regarding efficacy and the estimated number of preventable CRC deaths,34 and 
the participation rate estimated in the current study. The efficacy of FOBT in preventing 
CRC mortality was estimated at 38% from 3 randomized controlled trials, 1 
quasirandomized trial, and 8 case-control studies.34 Once adjusted for participation (24% 
and 26%, respectively), the screening program was estimated to reduce CRC deaths by 9% 
to 10%. Risk reductions were applied against an estimated 31,299 preventable CRC deaths 
per year.34
Sensitivity Analysis
We conducted several additional analyses to examine the sensitivity of the results of the 
current study to changes in participation rates, program costs, and anticipated increases in 
insurance coverage under the ACA. Results were examined by varying participation rates by 
25% and administrative costs by 25%, and reducing the number of uninsured adults by 50%. 
To account for the potential use of cooling bags to avoid the degradation of FIT by heat, we 
also examined the results when varying mailing and processing costs by 25%.
RESULTS
Scenario 1
Under the first scenario design, in which the FIT kit is first mailed to adults aged 50 years to 
75 years, the final participation rate of 24% would result in 8.7 million participants. Among 
those participating, 481,134 would have a positive FIT, with 360,850 individuals following 
up with a diagnostic colonoscopy (Table 1).16–29
The initial gross annual cost of a FIT-based program for those aged 50 years to 75 years was 
estimated at $344.9 million. The cost associated with testing is the largest component of 
overall costs, totaling approximately $177.7 million, which includes mailing the FIT kits, 
reminder letters, kit return costs, and test processing fees. The costs associated with 
diagnostic and surveillance colonoscopies among the uninsured population would be 
approximately $33.6 million, whereas administrative costs are estimated at $60.0 million 
and costs associated with improving participation and adherence are approximately $73.6 
million.
The modeled screening program would be expected to screen 8.7 million average-risk adults 
aged 50 years to 75 years for CRC with an initial additional investment of $318.2 million 
annually, and a cost per individual screened of $39.43. The screening program was 
estimated to prevent 2900 deaths annually.
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In the second scenario, in which a postcard is first mailed to all adults aged 50 years to 75 
years followed by a FIT kit to individuals expressing interest, the final participation rate of 
26% resulted in 9.4 million participants. Among those participating, 517,309 would have a 
positive FIT each year, with 387,982 individuals following up with a diagnostic 
colonoscopy (Table 2).16,20–30
The initial gross annual cost of a FIT-based program for those aged 50 years to 75 years was 
estimated at $304.6 million. The cost associated with testing is the largest component of 
overall costs, totaling approximately $129.3 million, which includes mailing the initial 
postcards, mailing the FIT kits, kit return costs, and test processing fees. The costs 
associated with diagnostic and surveillance colonoscopies among the uninsured population 
are approximately $36.1 million. Meanwhile, administrative costs are estimated at $60.0 
million, and the costs associated with improving participation and adherence are 
approximately $79.1 million.
The modeled screening program would be expected to screen 9.4 million average-risk adults 
aged 50 years to 75 years for CRC with an initial additional investment of $277.9 million 
annually, and a cost per individual screened of $32.38. The screening program was 
estimated to prevent 3100 deaths annually.
Sensitivity Analysis
Under the first scenario, varying the participation by 25% would result in a final 
participation rate of 18% to 30%, with 6.6 million to 10.9 million individuals screened. 
Variation in program costs resulted in an initial additional investment ranging from $273.8 
to $362.7 million annually, and a cost per person screened ranging from $34.35 to $44.51. 
With a 50% reduction in rates of uninsured individuals, the initial additional investment was 
estimated at $301.4 million annually, with a cost per person screened of $37.51 (Table 3).
In the second scenario, varying the final participation rate by 25% would result in a final 
participation rate of 19% to 32%, with 7.1 million to 11.8 million individuals screened. 
Variation in program costs resulted in an initial additional investment required ranging from 
$245.5 to $310.2 million annually, and a cost per person screened ranging from $28.95 to 
$35.82. With a 50% reduction in uninsurance rates, the initial additional investment was 
estimated at $259.8 million annually, with a cost per person screened of $30.46 (Table 3).
DISCUSSION
In the current study, we estimated the total initial investment required and the cost per 
person screened in a nationwide FIT-based screening program for adults aged 50 years to 75 
years. Under the first scenario, in which the initial mailing included the FIT kits, the initial 
additional investment required was estimated at $318.2 million annually, with an estimated 
8.7 million individuals screened for CRC at a cost of $39.43 per person screened. Under this 
scenario, the screening program was estimated to result in 2900 fewer deaths from CRC 
annually. Under the second intervention scenario, in which an invitation was mailed first, 
the initial additional investment required was estimated at $277.9 million annually, with an 
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estimated 9.4 million individuals screened for CRC at a cost of $32.38 per person screened. 
Under this scenario, the program was estimated to result in 3100 fewer deaths from CRC 
annually.
Organized CRC screening programs in other high-income countries have demonstrated the 
ability of such approaches to reach a substantial number of individuals at a modest cost per 
person screened. For example, a regional FOBT-based screening program in England 
screened 1.4 million people, and a national FOBT-based screening program in Germany 
screened 4.4 million people during the course of 1 year.35 The costs per person screened in 
organized FOBT-based screening programs are similar to those estimated in the current 
study. For example, a regional FOBT-based screening program in Portugal screened >6000 
individuals at a cost of $29 per person screened.35 A biennial FOBT-based screening 
program in Australia was estimated to screen 1 million people annually, with the cost per 
person screened ranging from $31 to $50.32
Organized CRC screening programs have demonstrated the ability to increase screening 
rates and reduce health disparities, both domestically and internationally. Kaiser Permanente 
has implemented an organized CRC screening program by using a mailed FIT. From 2005 to 
2011, they have increased screening rates from 37% to 75% among the privately insured 
population and from 41% to 85% among their managed Medicare population.13,36 A 
randomized controlled trial has shown mailed FIT outreach to be most effective in 
increasing CRC screening rates, compared with usual care and colonoscopy outreach.14 In 
Delaware, a statewide program providing coverage for CRC screening and treatment, patient 
navigation, and case management has increased CRC screening rates from 57% in 2002 to 
74% in 2009. The program also eliminated racial disparities in screening, incidence, and 
advanced stage of disease at the time of diagnosis.37 In Australia, data from the FIT-based 
National Bowel Cancer Screening Program demonstrated that individuals screened with 
mailed FIT kits were diagnosed at a significantly earlier stage of disease compared with 
those not invited, suggesting that the program will lead to reductions in CRC mortality in 
Australia.38
The success of the CDC’s National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP), which provides breast and cervical cancer screening to medically underserved 
low-income women, has been well documented. For example, between 1991 and 2006, 1.8 
million women were screened for breast cancer in the NBCCEDP, and the program saved 
100,800 life-years compared with no program.39 The cost estimates in the current study 
were considerably lower than those observed in the NBCCEDP. The cost per woman 
screened for breast cancer has been estimated at $108, whereas the cost per woman screened 
for cervical cancer was estimated at $65 in the NBCCEDP.40
Implementation of an organized population-based CRC screening program has the potential 
to make a significant public health impact by substantially increasing screening rates.13,36 
Using the results from the current study, if we assume that each individual screened in the 
first year was not up to date with CRC screening, after the first year of program 
implementation, the percentage of adults aged 50 years to 75 years being up to date would 
increase from 59% to approximately 86% to 88%. However, if we take a more conservative 
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approach and assume that only one-half of those newly screened were not up to date, the 
percentage of adults being up to date with screening would increase from 59% to 
approximately 72% to 73%.
Implementation of a FIT-based organized CRC screening program also has the potential to 
reduce CRC death rates and CRC treatment costs, at a modest cost per person screened. 
Consistent evidence has demonstrated that CRC screening among adults aged 50 years to 75 
years is effective in reducing incidence and mortality, and cost-effective.5,34 As 
demonstrated, organized CRC screening programs have the potential to eliminate health 
disparities37 and reduce CRC death rates.38 The rising costs of treating patients with 
advanced-stage CRC make screening a desirable approach to reduce incidence and 
mortality, and to control the cost of treatment.6 Increasing screening among adults aged 50 
years to 64 years, before Medicare eligibility, has the potential to substantially reduce the 
costs associated with CRC treatment in the Medicare population.7
The current study is subject to several limitations. First, annual program costs would likely 
be reduced after the initial 2 years of program implementation as individuals opt out or are 
up to date with screening. In addition, participants with a positive FIT receiving a normal 
follow-up colonoscopy would be up to date with CRC screening for the next 10 years, 
whereas those with abnormal results would have any polyps removed and enter a 
colonoscopy surveillance program. Second, these results are subject to the limitations of the 
data currently available and to our assumptions. For example, although our participation rate 
estimates were estimated based on studies conducted outside the United States, we also 
compared participation rates with randomized controlled trials in the United States among 
adults who were not up to date with CRC screening.14,41 As expected, our estimated 
participation rates (24%–26%) were lower than those observed in the previous studies 
(30%–44%) given the different study population.14,41 We examined the impact of higher 
participation rates in the sensitivity analyses in the current study. Third, our assumptions 
were based on data from the published literature; however, for several parameters, limited 
data were available. Fourth, we did not account for different positivity thresholds for the 
FIT, which can impact test results.13 Last, our modeling did not examine the cost-
effectiveness; however, previous studies have shown CRC screening to be very cost-
effective.5 The focus of the current study was to examine the costs of a national FIT-based 
CRC screening program from a program perspective. Additional modeling is warranted to 
examine the full costs and benefits from the societal perspective.
The substantial health and economic burden of CRC in the United States has made its 
prevention and early detection a public health priority in cancer prevention and control. 
Public health can help to guide cancer control approaches that are comprehensive, strategic, 
and organized to ensure that participation in cancer screening is widespread and equitable. 
Implementing a nationwide FIT-based CRC screening program would result in a substantial 
number of individuals screened at a moderate cost per person screened. Results from the 
current analysis may provide useful information for understanding the public health benefit 
of an organized screening delivery system as well as the potential resources required to 
implement a nationwide CRC screening program, and help guide decisions regarding 
program planning, design, and implementation.
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First intervention design of the colorectal cancer screening program is shown. FIT indicates 
fecal immunochemical test.
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Second intervention design of the colorectal cancer screening program is shown. FIT 
indicates fecal immunochemical test.
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TABLE 1
First Intervention Design: Mail FIT Kits to Adults Aged 50 to 75 Years
Participation and adherence
 82,114,360 US adults aged 50–75 y16
 41,057,180 No. offered screening each y (biennial screening)
 6,577,360 Initial participantsa based on 18% participation rate18
 33% Increase in participation from reminder letters19
 8,747,889 Final participants, based on 24% final participation rate18,19
 5.5% Percentage with positive findings20
 481,134 Positive tests
 75% Colonoscopy adherence21–23
 360,850 New diagnostic colonoscopies
 72% Percentage of colonoscopies that will find adenomas or cancer and require surveillance20
 259,812 No. that will enter surveillance colonoscopy program
 416,277 Annual no. of colonoscopies for program (diagnostic and surveillance)
Cost assumptions
 FIT kit costs
  $82,114,360 Kit mailing fee ($2 each)
  $17,495,778 Kit return fee ($2 each)
  $16,833,444 Reminder letters ($.50 each)
  $61,235,224 Test processing fees ($7 each)
 Colonoscopy and associated medical costsb
  $3,156,238 Primary care visits (80% with a positive test will see a PCP; $82 per visit)24
  $30,223,665 Colonoscopies ($727 cost per colonoscopy)25
  $259,476 Colonoscopy complications (2.4 per 1000 colonoscopies; $6233 cost per complication)17,24,26–28
 Improving participation and adherence
  $73,613,487 Improving participation and adherence ($153 per positive FIT)29
 Program administrative costs
  $60,000,000 General program administrative costs
 Cost offsets
  $26,700,000 Current annual spending on screening program
Abbreviation: FIT, fecal immunochemical test; PCP, primary care provider.
a
Excludes 11% of adults with a family history of colorectal cancer.17
b
Costs included only for the uninsured population aged 50 years to 64 years (10% of sample).
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TABLE 2
Second Intervention Design: Mail Advanced Notification Postcard Followed by FIT Kit to Adults Aged 50 to 
75 Years
Participation and adherence
 82,114,360 US adults aged 50 to 75 y16
 41,057,180 No. offered screening each y (biennial screening)
 12,058,494 Would express interest in participatinga based on 33% participation rate30
 78% Return rate of mailed FIT kits30
 9,405,625 Final participants, based on 26% participation rate30
 5.5% Percentage with positive findings20
 517,309 Positive tests
 75% Colonoscopy adherence21–23
 387,982 New diagnostic colonoscopies
 72% Percentage of colonoscopies that will find adenomas or cancer and require surveillance20
 279,347 Will enter surveillance colonoscopy program
 447,576 Annual no. of colonoscopies for program (diagnostic and surveillance)
Cost assumptions
 FIT kit costs
  $20,528,590 Kit mailing fee ($2 each)
  $24,116,988 Kit return fee ($2 each)
  $18,811,250 Reminder letters ($.50 each)
  $65,839,376 Test processing fees ($7 each)
 Colonoscopy and associated medical costsb
  $3,393,550 Primary care visits (80% with a positive test will see a PCP; $82 per visit)24
  $32,496,121 Colonoscopies ($727 cost per colonoscopy)25
  $236,428 Colonoscopy complications (2.4 per 1000 colonoscopies; $6233 cost per complication)17,24,26–28
 Improving participation and adherence
  $79,148,336 Improving participation and adherence ($153 per positive FIT)29
 Program administrative costs
  $60,000,000 General program administrative costs
 Cost offsets
  $26,700,000 Current annual spending on screening program
Abbreviation: FIT, fecal immunochemical test; PCP, primary care provider.
a
Excludes 11% of adults with a family history of colorectal cancer.17
b
Costs included only for the uninsured population aged 50 to 64 years (10% of sample).
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TABLE 3
Results of Sensitivity Analyses of Varying Participation Rates, Costs Associated With FIT Kit Mailing and 
Processing, and Administrative Costs
Intervention Design 1 Intervention Design 2
Total Additional Investment Cost Per Person Screened Total Additional Investment
Cost Per Person 
Screened
Base case $318.2 million $39.43 $277.9 million $32.38
Participation rate
 25% increase $364.7 million $35.80 $327.9 million $30.16
 25% decrease $271.7 million $45.49 $227.9 million $36.09
Costs associated mailing and processing
 25% increase $362.7 million $44.51 $310.2 million $35.82
 25% decrease $273.8 million $34.35 $245.5 million $28.95
Administrative costs
 25% increase $333.2 million $41.14 $292.9 million $33.98
 25% decrease $303.2 million $37.72 $262.9 million $30.79
Uninsurance rates
 50% reduction $301.4 million $37.51 $259.8 million $30.46
Abbreviation: FIT, fecal immunochemical test.
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